RAPID MICRO BIOSYSTEMS INC
Rapid Micro Biosystems (RPID) develops rapid microbial detection instruments and consumables used by pharmaceutical and biotech manufacturers to monitor contamination in drug production and sterile processes. Its systems aim to speed up bioburden and sterility testing compared with traditional culture methods, which can shorten release times and improve manufacturing efficiency. The company is still relatively small (market cap around $130m) and may be unprofitable or cash‑flow negative as it invests in commercial rollout and product development. Key investor considerations include adoption by regulated customers, recurring revenue from consumables, competition from established lab suppliers, and regulatory scrutiny. As with any small medical‑technology company, shares can be volatile and subject to execution and reimbursement risks. This is general educational information and not personal advice; investors should assess suitability against their objectives, risk tolerance and time horizon, and consider seeking independent financial advice.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Rapid Micro Biosystems' stock with a target price of $4.75, indicating strong growth potential.
Financial Health
RAPID MICRO BIOSYSTEMS INC shows stable revenue and cash flow, but its overall financial position needs improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring RPID
Pharma Onshoring Boom: Investment Risk Considerations
AstraZeneca is building a major new manufacturing plant in the U.S., responding to policy pressures for domestic production. This signals a broader trend of onshoring pharmaceutical manufacturing, creating opportunities for companies that build and equip these advanced facilities.
Published: October 10, 2025
Explore BasketPharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: July 23, 2025
Explore BasketMicrobiome Modulators
Discover a carefully selected group of innovative biotechnology companies leveraging the untapped power of the body's microbiome. These pioneering firms are creating revolutionary therapies that target the root causes of disease by rebalancing our internal microbial ecosystems.
Published: June 17, 2025
Explore BasketGarage Innovators
Meet the companies that are inventing tomorrow, today. These stocks represent businesses with exceptional in-house research and development, carefully selected by professional analysts for their ability to create breakthrough products and technologies from within.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Faster contamination detection
Systems aim to shorten bioburden and sterility testing times, which can improve manufacturing throughput — though clinical and regulatory validation is essential and outcomes can vary.
Recurring consumables model
Recurring sales of single‑use consumables can support predictable revenue as installed base grows, but revenue depends on customer adoption and usage rates.
Regulatory & adoption hurdles
Commercial success relies on uptake by regulated pharma customers and acceptance from quality teams; regulatory scrutiny and strong incumbents create execution risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
